BridgeBio reported positive top-line results from the global Phase 3 Propel 3 trial of oral infigratinib in children with achondroplasia, meeting the primary endpoint of increased annualized height velocity. The drug produced a statistically significant improvement versus placebo and achieved the highest LS mean absolute growth velocity reported to date in a randomized achondroplasia study. BridgeBio said it will meet with regulators to discuss marketing submissions planned later this year and intends to accelerate development in hypochondroplasia. Analysts note the oral FGFR3 inhibitor could become a competitor to existing injectable therapies if regulators accept the data and safety profile; BridgeBio flagged mild, transient hyperphosphatemia in a small number of patients.